Discovery of co-occurring driver pathways in cancer

Junhua Zhang1, Ling-Yun Wu, Xiang-Sun Zhang

  • 1National Center for Mathematics and Interdisciplinary Sciences, Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing 100190, China. zjh@amt.ac.cn.

BMC Bioinformatics
|August 10, 2014
PubMed
Abstract

Insights

This study introduces a new mathematical method to find cooperating mutated driver pathways in cancer. This approach identifies gene sets involved in crucial biological processes, improving cancer mechanism understanding.

Area of Science:

  • Computational biology
  • Cancer genomics
  • Systems biology

Background:

  • Carcinogenesis is driven by complex pathway interactions, not just individual genes.
  • Previous research focused on single gene or pathway alterations.
  • Cooperative pathway function is critical in cancer development.

Purpose of the Study:

  • To develop a novel computational method for identifying co-occurring mutated driver pathways (CoMDP).
  • To analyze cooperative pathway interactions in carcinogenesis using mutation profiles.
  • To advance understanding of molecular mechanisms in cancer.

Main Methods:

  • Developed an exact mathematical programming method for de novo pathway identification.
  • Exploited pathway coverage, exclusivity, and mutation co-occurrence properties.
  • Validated the method on simulated data and applied it to glioblastoma, lung adenocarcinoma, and ovarian carcinoma datasets.

Main Results:

  • Successfully identified co-occurring mutated driver pathways (CoMDP).
  • Discovered pathways involved in essential biological processes like cell survival and protein synthesis.
  • Demonstrated method's ability to identify additional or multiple co-occurring pathways.

Conclusions:

  • The proposed method identifies gene sets with greater biological relevance than single-pathway approaches.
  • Offers a powerful tool for uncovering cooperative pathway roles in carcinogenesis.
  • Enhances the discovery of driver pathways for improved cancer treatment strategies.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K